Merck's Fosamax Patent Reinstated In E.U.
In a surprise victory for Merck & Co., the European Patent Office reinstated Wednesday the drug maker's critical patent for its osteoporosis drug Fosamax Once Weekly, nearly three years after it...To view the full article, register now.
Already a subscriber? Click here to view full article